AstraZeneca Pharma India share news, announcements and annual reports
NSE: ASTRAZENBSE: 506820Pharmaceuticals & BiotechnologySmall Cap
AstraZeneca Pharma India Limited · Formerly Astra IDL · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1982 on BSE, May 2001 on NSE
Last close ₹6,364.50up ₹65.50 (1.04%)BSE ₹6,367.35
Share price at the NSE close on 30 Oct 2026. Previous close ₹6,299.00.
30 Oct: open ₹6,300.00, high ₹6,380.00, low ₹6,240.50
52-week range of traded prices to 30 Oct 2026
₹5,640.00Low, 9 Oct 2026₹9,849.50High, 3 Nov 2025
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,911 Cr333rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 93.81
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 18.23
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.57%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 24.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 6,84556.8% delivered
AstraZeneca Pharma India dividends
17 filed, newest first.
May 2025
May 2024
27 May · Dividend
May 2023
30 May · Dividend
May 2022
27 May · Dividend
Aug 2021
Sep 2020
8 Sep · Dividend
Aug 2020
10 Aug · Dividend
Aug 2019
7 Aug · Dividend
May 2012
12 May · Dividend
Board of Directors of the Company at its meeting held on May 11, 2012 has recommended a dividend of Rs.3.50/- per Equity Share of face value of Rs.2/- each (175%) for the Financial Year ended March 31, 2012, subject to the approval of the shareholders at the ensuing Annual General Meeting.
Jul 2011
18 Jul · Dividend
July 28, 2011 will be the Dividend payout date for payment of Dividend to the members.
Jun 2011
9 Jun · Dividend
Board of Directors of the Company at its meeting held on May 13, 2011 has recommended a dividend of Rs 10/- per Equity Share of a face value of Rs 2/- each for the Financial Year (15 months period) ended March 31, 2011, subject to the approval of the shareholders at the ensuing Annual General Meeting.
Feb 2010
23 Feb · Dividend
Board of Directors of the company in its meeting held on February 23, 2010 have recommended a dividend of Rs. 10/- per Equity Share of face value of Rs. 2/- each for the year ended December 31, 2009, subject to the approval of the shareholders at the ensuing Annual General Meeting.
Feb 2009
18 Feb · Dividend
Board at its meeting held on February 18, 2009 has recommended a Dividend of Rs. 15/- per Equity Share of face value of Rs. 2/- each, subject to the approval of the shareholders at the ensuing Annual General Meeting scheduled to be held on May 18, 2009.
Mar 2007
19 Mar · Dividend
At the Meeting held today i.e. 17th march, 2007 the Board of Directors of the Company have inter-alia transacted/approved the following: (1) The Board of Directors revoked the dividend of Rs.12/- per equity share (face value of Rs. 2/- each), recommended earlier at its meeting held on February 23, 2007. (2) The Board has declared an Interim Dividend of Rs.12/- per equity share (face value of Rs. 2/- each), for the year ended December 31, 2006. As informed earlier, March 24, 2007 has been fixed as the Record Date for the purpose of payment of Interim Dividend. (3) Revised Audited Accounts for the year ended December 31, 2006, after necessary changes as to revocation of recommended dividend and payment of Interim Dividend as above, was approved by the Board. (4) The Register of Members and Share Transfer Books of the Company shall remain closed from 27th to 30th April 2007 (both days inclusive) for the ensuing Annual General Meeting scheduled on April 30, 2007